Literature DB >> 3841378

Pharmacokinetics of methimazole in humans.

J H Hengstmann, H Hohn.   

Abstract

A newly developed method for extracting and measuring methimazole in biological fluids was used to study the pharmacokinetics of methimazole in two euthyroid and eight hyperthyroid subjects. The volume of distribution approximated total body water; the biological half-life was 2-3 h in euthyroid and about 6 h in hyperthyroid patients. Total clearance was lower in hyperthyroid patients than in euthyroid subjects, and it did not increase after thyroid function was normalized. Bioavailability in euthyroid subjects was greater than 1 but only 0.5 in hyperthyroid subjects. The reasons for these observed differences are not known.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841378     DOI: 10.1007/bf01733780

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Fatal marrow aplasia after treatment with carbimazole.

Authors:  C D BURRELL
Journal:  Br Med J       Date:  1956-06-23

2.  Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients.

Authors:  G G Skellern; J B Stenlake; W D Williams; D G McLarty
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  Relation between thyroid iodine content and the accumulation and oxidation of [35-S] Methimazole in the rat.

Authors:  B Marchant; P D Papapetrou; W D Alexander
Journal:  Endocrinology       Date:  1975-07       Impact factor: 4.736

4.  Methimazole: its absorption and excretion in man and tissue distribution in rats.

Authors:  J A Pittman; R J Beschi; T C Smitherman
Journal:  J Clin Endocrinol Metab       Date:  1971-08       Impact factor: 5.958

5.  Comparative bioavailability of carbimazole and methimazole.

Authors:  R Jansson; P A Dahlberg; B Lindström
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-10

6.  Intrathyroidal concentrations of methimazole in patients with Graves' disease.

Authors:  R Jansson; P A Dahlberg; H Johansson; B Lindström
Journal:  J Clin Endocrinol Metab       Date:  1983-07       Impact factor: 5.958

7.  [Serum level and urinary excretion of 14C-thiamozol in patients with hyperthyroidism (author's transl)].

Authors:  J Balzer; H G Lahrtz; P A van Zwieten
Journal:  Dtsch Med Wochenschr       Date:  1975-03-14       Impact factor: 0.628

8.  Methimazole: an alternative route of administration.

Authors:  N Nabil; D J Miner; J M Amatruda
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

9.  The mechanism of action of the thioureylene antithyroid drugs.

Authors:  A Taurog
Journal:  Endocrinology       Date:  1976-04       Impact factor: 4.736

10.  The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.

Authors:  G G Skellern; B I Knight; C K Low; W D Alexander; D G McLarty; W J Kalk
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

View more
  2 in total

1.  Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-Throughput in vitro Data, High-Throughput Exposure Modeling, and Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Jeremy A Leonard; Yu-Mei Tan; Mary Gilbert; Kristin Isaacs; Hisham El-Masri
Journal:  Toxicol Sci       Date:  2016-02-10       Impact factor: 4.849

2.  Pharmacologic treatment of hyperthyroidism during lactation.

Authors:  Miguel Marcelo Glatstein; Facundo Garcia-Bournissen; Norberto Giglio; Yaron Finkelstein; Gideon Koren
Journal:  Can Fam Physician       Date:  2009-08       Impact factor: 3.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.